Cogent Biosciences’ bezuclastinib demonstrated statistically significant improvements in indolent systemic mastocytosis during a registrational Phase II study, producing meaningful symptomatic relief and clinical benefit. The company is advancing toward an NDA submission with these data. Analysts viewed the trial outcomes favorably, considering it competitive with existing KIT-targeting agents. Positive signals elevate Cogent’s profile in the mast cell disorder treatment landscape.